查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830964

肺部给药系统市场

Pulmonary Drug Delivery Systems Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

预计肺部给药系统市场将从 2024 年的 541.4 亿美元成长到 2031 年的 731.4 亿美元，2025 年至 2031 年的复合年增长率为 4.4%。

市场洞察与分析师观点：肺部给药系统旨在透过吸入将气雾剂直接输送至上皮细胞和呼吸道上皮。这些系统包括吸入器和雾化器等装置，可将药物输送至肺部以治疗呼吸系统疾病。肺部给药装置采用各种药物剂型及输送机制。需要使用这些装置治疗的主要呼吸系统疾病包括气喘、慢性阻塞性肺病 (COPD)、急性呼吸道感染、过敏性鼻炎和囊性纤维化。呼吸系统疾病的盛行率不断上升，加上企业的策略性倡议，正在推动肺部给药系统市场的成长。值得注意的趋势包括吸入器技术的进步，预计这些技术将在未来几年进一步推动市场成长。

成长催化剂：肺部给药系统领域的企业持续推行策略倡议，例如合作、协议、伙伴关係和新产品推出。这些策略能够提升销售额，扩大地域覆盖，并提升服务更广泛客户群的能力。新产品的推出主要旨在提升安全性、用户友善性和剂量准确性，以吸引更广泛的患者群体。以下是肺部给药系统市场的一些重要发展：

2021 年 9 月，BreatheSuite Inc. 的 BreatheSuite 定量吸入器 V1 获得了美国 FDA 的 510(K) 许可，可用于处方药和非处方药。该设备透过自动监测气喘和 COPD 患者的吸入依从性和技术并提供回馈，将标准定量吸入器转变为智慧吸入器。 2021 年 6 月，Glenmark Pharmaceuticals Ltd 在英国推出了 Tiogiva，这是噻托溴铵干粉吸入器的生物等效版本，用于治疗 COPD。 2021 年 4 月，KINDEVA DRUG DELIVERY 与 Cambridge Healthcare Innovations Limited (CHI) 合作，开发和商业化 CHI 的 aeolus 干粉吸入器 (DPI) 平台技术。 2020 年 12 月，数位健康创新者 AireHealth 的连接雾化器获得了 510(k) 许可，这是一款便携式电子振动网状雾化器，用于雾化液体药物供患者吸入，以 VitalMed 的品牌销售。 2020 年 9 月，葛兰素史克公司和 Innoviva, Inc. 获得 FDA 批准使用 Trelegy Ellipta 是美国首个针对 18 岁及以上气喘和 COPD 患者的每日一次单吸入性三合一疗法。因此，公司为保持竞争力而采取的策略性倡议和产品发布越来越多，正在推动肺部药物输送系统市场的成长。

策略洞察报告细分与范围：肺部给药系统市场分析涵盖以下几个面向：产品、适应症、配销通路、最终用户和地理。产品领域包括干粉吸入器、雾化器和定量吸入器。适应症领域分为慢性阻塞性肺病、气喘、囊性纤维化等。配销通路领域包括医院药房、零售药房和电子商务。最终用户领域分为医院和诊所以及家庭护理。肺部药物输送系统市场报告的范围涵盖北美（美国、加拿大和墨西哥）、欧洲（法国、德国、英国、西班牙、义大利和欧洲其他地区）、亚太地区（中国、日本、印度、韩国、澳洲和亚太其他地区）、中东和非洲（沙乌地阿拉伯、南非、阿联酋和中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和其他地区）。

細項分析：肺部给药系统市场依产品分为干粉吸入器、雾化器和定量吸入器。干粉吸入器细分市场在2023年占据了相当大的市场份额，预计在2023年至2031年期间的复合年增长率最高。

根据适应症，肺部给药系统市场分为慢性阻塞性肺病、气喘、囊性纤维化等。慢性阻塞性肺病领域在2023年占据了显着的市场份额，预计在2023年至2031年期间将经历最高的复合年增长率。

就配销通路而言，市场细分为医院药房、零售药房和电商。 2023年，医院药局占据了肺部给药系统市场的很大份额，而电商预计将在2023年至2031年期间实现最高的复合年增长率。

就终端用户而言，肺部给药系统市场分为医院和诊所以及家庭护理。医院和诊所在2023年占据了相当大的市场份额，而家庭护理市场预计在2023年至2031年期间将实现更高的复合年增长率。

区域分析：从地理上讲，肺部给药系统市场分为北美、欧洲、亚太地区、南美和中美以及中东和非洲。 2023 年，北美占据了相当大的市场份额，其中美国是该地区最大的贡献者。北美市场的成长是由气喘和 COPD 等呼吸系统疾病的盛行率不断上升、老龄人口不断增长、诊断设备需求不断增长以及主要市场参与者的强大影响力所推动的。根据美国疾病管制与预防中心 (CDC) 2020 年的数据，美国约有 5.0% 的成年人被诊断出患有 COPD 或慢性支气管炎，约有 2500 万人患有气喘，1480 万人患有 COPD。此外，加拿大护理师协会估计，约有 300 万加拿大人患有严重的呼吸系统疾病，包括 COPD、囊性纤维化、气喘和职业性肺病。

加拿大肺臟协会报告称，呼吸系统疾病是住院率第三高的疾病，约五分之一的加拿大人患有严重的呼吸系统疾病，例如气喘、慢性阻塞性肺病、肺癌、肺结核、囊性纤维化和呼吸窘迫症候群。各种呼吸系统疾病患者数量的不断增加，推动了对创新有效的肺部给药系统（例如定量吸入器和雾化器）的需求。

肺部给药系统市场报告范围：产业发展与未来机会：肺部给药系统市场报告包含对公司定位和集中度的分析，以评估竞争格局。根据各公司新闻稿，以下是市场主要参与者采取的一些措施：

2021年3月，PARI Pharma GmbH获得LAMIRA雾化器系统的授权，用于在日本输送Insmed的药品ARIKAYCE（阿米卡星脂质体吸入混悬液）。此前，美国和欧洲已批准了ARIKAYCE，Insmed也于2021年3月获得日本厚生劳动省的批准。 2020年12月，欧盟委员会批准阿斯特捷利康的Trixeo Aerosphere在欧盟用于治疗慢性阻塞性肺病（COPD），该药物专为中度至重度COPD成年患者设计。 Trixeo Aerosphere是一种单吸入器，由富马酸福莫特罗、格隆溴铵和布地奈德组成，透过加压定量吸入器输送。竞争格局与关键参与者：肺部给药系统市场的预测可以帮助利害关係人规划其成长策略。市场的主要参与者包括阿斯特捷利康、葛兰素史克、诺华、荷兰皇家飞利浦、勃林格殷格翰国际有限公司、西普拉公司、欧姆龙公司、PARI GmbH、Glenmark Pharmaceuticals 和 Gilbert Technologies。这些公司专注于推出新的高科技产品、增强现有产品组合併拓展业务范围，以满足日益增长的全球消费者需求。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：肺部给药系统市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：肺部给药系统市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：肺部给药系统市场－全球市场分析

  • 肺部给药系统－全球市场概览
  • 肺部给药系统－全球市场及2031年预测

第七章：肺部给药系统市场-收入分析-按产品，2021-2031

  • 概述
  • 干粉吸入器
  • 定量吸入器
  • 雾化器

第 8 章：肺部给药系统市场 - 收入分析 - 按适应症，2021-2031 年

  • 概述
  • 慢性阻塞性肺臟疾病
  • 气喘
  • 囊肿纤维化
  • 其他的

第九章：肺部给药系统市场-收入分析-按配销通路，2021-2031

  • 概述
  • 医院药房
  • 零售药局
  • 电子商务

第 10 章：肺部给药系统市场 - 收入分析 - 按最终用户，2021-2031 年

  • 概述
  • 医院和诊所
  • 居家护理

第 11 章：肺部给药系统市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 12 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 13 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 14 章：肺部给药系统市场 - 关键公司简介

  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Koninklijke Philips NV
  • Cipla Inc.
  • OMRON Corp.
  • PARI GmbH
  • Glenmark Pharmaceuticals
  • Gilbert Technologies

第 15 章：附录

简介目录
Product Code: TIPHE100001256

The pulmonary drug delivery systems market is anticipated to grow from US$ 54.14 billion in 2024 to US$ 73.14 billion by 2031, reflecting a CAGR of 4.4% from 2025 to 2031.

Market Insights and Analyst Perspective:Pulmonary drug delivery systems are designed to administer aerosols directly to the epithelial cells and respiratory epithelium via inhalation. These systems encompass devices like inhalers and nebulizers that deliver medications to the lungs for treating respiratory conditions. Various drug formulations and delivery mechanisms are utilized in pulmonary drug delivery devices. Key respiratory diseases necessitating these devices include asthma, chronic obstructive pulmonary disease (COPD), acute respiratory infections, allergic rhinitis, and cystic fibrosis. The rising prevalence of respiratory diseases, along with strategic initiatives from companies, is driving the growth of the pulmonary drug delivery systems market. Notable trends include advancements in inhaler technologies that are expected to further boost market growth in the coming years.

Growth Catalysts:Firms in the pulmonary drug delivery systems sector are consistently pursuing strategic initiatives such as collaborations, agreements, partnerships, and new product introductions. These strategies enhance their sales, expand their geographic presence, and improve their ability to cater to a larger customer base. New product launches are primarily aimed at enhancing safety, user-friendliness, and dosing accuracy to attract a broader patient demographic. Below are some significant developments in the pulmonary drug delivery systems market:

In September 2021, BreatheSuite Inc. obtained 510(K) clearances from the US FDA for its BreatheSuite metered-dose inhaler V1, intended for both prescription and over-the-counter use. This device transforms standard metered-dose inhalers into smart inhalers by automatically monitoring and providing feedback on inhaler adherence and technique for asthma and COPD patients.

In June 2021, Glenmark Pharmaceuticals Ltd launched Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler, in the UK for COPD treatment.

In April 2021, KINDEVA DRUG DELIVERY partnered with Cambridge Healthcare Innovations Limited (CHI) to develop and commercialize CHI's aeolus dry-powder inhaler (DPI) platform technology.

In December 2020, AireHealth, a digital health innovator, received 510(k) clearance for its connected nebulizer, a portable electronic vibrating mesh nebulizer designed for nebulizing liquid medications for patient inhalation, marketed as VitalMed.

In September 2020, GlaxoSmithKline plc and Innoviva, Inc. secured FDA approval for Trelegy Ellipta, the first once-daily single inhaler triple therapy for asthma and COPD patients aged 18 and older in the US.Therefore, the increasing number of strategic initiatives and product launches by companies to maintain competitiveness is driving the growth of the pulmonary drug delivery systems market.

Strategic Insights

Report Segmentation and Scope:The analysis of the pulmonary drug delivery systems market has been conducted by examining the following segments: product, indication, distribution channel, end user, and geography. The product segment includes dry powder inhalers, nebulizers, and metered dose inhalers. The indication segment is classified into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. The distribution channel segment includes hospital pharmacies, retail pharmacies, and e-commerce. The end user segment is divided into hospitals & clinics and homecare. The scope of the pulmonary drug delivery systems market report encompasses North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The pulmonary drug delivery systems market is categorized by product into dry powder inhalers, nebulizers, and metered dose inhalers. The dry powder inhalers segment accounted for a significant market share in 2023 and is expected to exhibit the highest CAGR from 2023 to 2031.

By indication, the pulmonary drug delivery systems market is classified into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. The chronic obstructive pulmonary diseases segment held a notable market share in 2023 and is projected to experience the highest CAGR during 2023 to 2031.

In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment captured a significant share of the pulmonary drug delivery systems market in 2023, while the e-commerce segment is anticipated to achieve the highest CAGR from 2023 to 2031.

Regarding end user, the pulmonary drug delivery systems market is divided into hospitals & clinics and homecare. The hospitals & clinics segment held a substantial market share in 2023, whereas the homecare segment is expected to register a higher CAGR during 2023 to 2031.

Regional Analysis:Geographically, the pulmonary drug delivery systems market is divided into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America held a significant market share, with the US being the largest contributor in the region. The growth of the market in North America is driven by the increasing prevalence of respiratory diseases such as asthma and COPD, a growing elderly population, rising demand for diagnostic devices, and the strong presence of key market players. According to the Centers for Disease Control and Prevention (CDC) in 2020, approximately 5.0% of adults in the US are diagnosed with COPD or chronic bronchitis, with around 25 million individuals affected by asthma and 14.8 million suffering from COPD. Additionally, the Canadian Nurse Association estimates that about 3 million Canadians are afflicted with serious respiratory diseases, including COPD, cystic fibrosis, asthma, and occupational lung diseases.

The Canadian Lung Association reports that respiratory diseases account for the third highest rate of hospitalizations, with approximately one in five Canadians suffering from serious respiratory conditions such as asthma, COPD, lung cancer, tuberculosis, cystic fibrosis, and respiratory distress syndrome. The increasing number of patients with various respiratory diseases is driving the demand for innovative and effective pulmonary drug delivery systems, such as metered dose inhalers and nebulizers.

Pulmonary Drug Delivery Systems Market Report Scope

Industry Developments and Future Opportunities:The pulmonary drug delivery systems market report includes an analysis of company positioning and concentration to assess the competitive landscape. Based on company press releases, here are some initiatives undertaken by key players in the market:

In March 2021, PARI Pharma GmbH received authorization for the LAMIRA Nebulizer System to deliver Insmed's drug product ARIKAYCE (amikacin liposome inhalation suspension) in Japan. Insmed received approval for ARIKAYCE from Japan's Ministry of Health, Labour, and Welfare in March 2021, following earlier approvals in the US and Europe.

In December 2020, the European Commission approved AstraZeneca's Trixeo Aerosphere for COPD treatment in the European Union, designed for adult patients with moderate to severe COPD. Trixeo Aerosphere is a single-inhaler, fixed-dose combination of formoterol fumarate, glycopyrronium bromide, and budesonide, delivered via a pressurized metered-dose inhaler.

Competitive Landscape and Key Players:The forecast for the pulmonary drug delivery systems market can assist stakeholders in planning their growth strategies. Key players in the market include AstraZeneca, GlaxoSmithKline Plc, Novartis AG, Koninklijke Philips NV, Boehringer Ingelheim International GmbH, Cipla Inc., OMRON Corp., PARI GmbH, Glenmark Pharmaceuticals, and Gilbert Technologies. These companies are focused on launching new high-tech products, enhancing existing offerings, and expanding geographically to meet the increasing global consumer demand.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Pulmonary Drug Delivery Systems Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Pulmonary Drug Delivery Systems Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Pulmonary Drug Delivery Systems Market - Global Market Analysis

  • 6.1 Pulmonary Drug Delivery Systems - Global Market Overview
  • 6.2 Pulmonary Drug Delivery Systems - Global Market and Forecast to 2031

7. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Product, 2021-2031

  • 7.1 Overview
  • 7.2 Dry Powder Inhalers
  • 7.3 Metered Dose Inhalers
  • 7.4 Nebulizers

8. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Indication, 2021-2031

  • 8.1 Overview
  • 8.2 Chronic Obstructive Pulmonary Disease
  • 8.3 Asthma
  • 8.4 Cystic Fibrosis
  • 8.5 Others

9. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 E-commerce

10. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 10.1 Overview
  • 10.2 Hospitals and Clinics
  • 10.3 Homecare

11. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Pulmonary Drug Delivery Systems Market Overview
    • 11.1.2 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts to 2031
    • 11.1.3 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Product
    • 11.1.4 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Indication
    • 11.1.5 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 11.1.6 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By End User
    • 11.1.7 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Pulmonary Drug Delivery Systems Market
        • 11.1.7.1.1 United States Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.1.2 United States Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.1.3 United States Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.1.4 United States Pulmonary Drug Delivery Systems Market, by End User
      • 11.1.7.2 Canada Pulmonary Drug Delivery Systems Market
        • 11.1.7.2.1 Canada Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.2.2 Canada Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.2.3 Canada Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.2.4 Canada Pulmonary Drug Delivery Systems Market, by End User
      • 11.1.7.3 Mexico Pulmonary Drug Delivery Systems Market
        • 11.1.7.3.1 Mexico Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.3.2 Mexico Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.3.3 Mexico Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.3.4 Mexico Pulmonary Drug Delivery Systems Market, by End User
  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Pulmonary Drug Delivery Systems Market - Key Company Profiles

  • 14.1 AstraZeneca plc
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Boehringer Ingelheim International GmbH
  • 14.3 GlaxoSmithKline plc
  • 14.4 Novartis AG
  • 14.5 Koninklijke Philips NV
  • 14.6 Cipla Inc.
  • 14.7 OMRON Corp.
  • 14.8 PARI GmbH
  • 14.9 Glenmark Pharmaceuticals
  • 14.10 Gilbert Technologies

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud